Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan

BACKGROUND: Real-world impact of extended-release formulations of oral drugs should ideally be evaluated in population-based health data. OBJECTIVE: To evaluate changes in utilization of the dopamine agonist pramipexole for Parkinson’s disease after the introduction of extended-release (ER) pramipex...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, K. Arnold, Hsieh, Yu-Chun, Hsieh, Shu-Feng, Chen, Rou-Shayn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984130/
https://www.ncbi.nlm.nih.gov/pubmed/33067761
http://dx.doi.org/10.1007/s40801-020-00215-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984130/
https://www.ncbi.nlm.nih.gov/pubmed/33067761
http://dx.doi.org/10.1007/s40801-020-00215-6

Ejemplares similares